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Prior exposure to dengue virus (DENV) has a profound impact on the outcome of
infection, which varies according to the interval between infections. Antibodies secreted
by B cells and cytokines secreted by T cells are thought to contribute both to protective
immunity against DENV and the pathogenesis of dengue disease.We analyzed peripheral
blood mononuclear cells (PBMC) collected from Thai children over a 5-year prospective
cohort study to define the dynamics of DENV-specific memory B and T cell responses
and the impact of symptomatic or subclinical DENV infections. To measure B cell
responses, PBMC were stimulated with IL-2 plus R848 and culture supernatants were
tested for DENV-binding antibodies by ELISA. To measure T cell responses, PBMC were
stimulated in dual-color ELISPOT assays with overlapping peptide pools of structural
and non-structural proteins from the four DENV types. B cell responses were low to
one or more DENV types prior to symptomatic infection and increased with reactivity to
all four types after infection. Subjects who had a subclinical infection or who did not
experience a DENV infection during the study period showed strong memory B cell
responses to all four DENV types. T cell responses to DENV peptides demonstrated
a cytokine hierarchy of IFN-γ > IL-2 > IFN-γ/IL-2. T cell responses were low or absent
prior to secondary infections. The trends in T cell responses to DENV peptides over 3
year post-infection were highly variable, but subjects who had experienced a secondary
DENV1 infection showed higher cytokine responses compared to subjects who had
experienced a secondary DENV2 or subclinical infection. The longitudinal nature of our
study demonstrates persistent memory B cell responses over years and a lasting but
variable impact of secondary DENV infection on DENV-specific T cell responses.
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INTRODUCTION
Immune memory is the hallmark of the adaptive immune
response. The generation and persistence of memory B and T
cells are key to protection against a subsequent infection with
a pathogen and are the principles behind effective vaccination.
Most of our understanding of durable adaptive immune
responses to viruses comes from mouse models where pathogens
are administered in germ-free environments under controlled
conditions. Studies in mice, however, do not recapitulate the
exposure in humans to multiple pathogens or even different
strains of the same pathogen over time.
Dengue is the most important arthropod-borne viral disease
caused by infection with any of the four dengue virus serotypes
(DENV1-4) (1, 2). Most infections are subclinical but in some
cases lead to clinical symptoms ranging from mild febrile illness
(dengue fever, DF) to the life-threatening dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) (3). A primary
infection with any of the four DENV serotypes elicits long-
lasting homotypic immunity (4, 5), although there are a few
reported cases of homotypic reinfections (6–9). In endemic areas,
periodic inapparent exposures to DENV may boost this DENV-
specific immunity (10–12). However, infection with a different
DENV serotype (heterotypic secondary infection) is associated
with an increased risk for DHF/DSS (4, 5, 13). Both antibodies
and T cells are hypothesized to contribute to this increased risk
of severe disease through a variety of mechanisms, although
other data point to their ability to protect against severe DENV
disease (14–20). Furthermore, evidence for a lower risk of severe
disease during third or fourth DENV infections suggests that the
cumulative effects of cross-reactive memory immune responses
are beneficial (21–23).
The degree to which B and T cell immune responses
remain stable or fluctuate over time after DENV infection may
influence the balance between protective and detrimental effects
of DENV-specific immune responses, but remains relatively
poorly characterized. In a prospective cohort study conducted
in Kamphaeng Phet province in north-central Thailand, we
collected peripheral blood mononuclear cells (PBMC) over a 5-
year period from children who were followed for the occurrence
of DENV infections. These samples provided the opportunity
to analyze the dynamics, magnitude, and durability of memory
B and T cell responses to DENV over an extended period.
We found that both B and T cell responses were low before
symptomatic infection and increased after infection, albeit with
different kinetics. In contrast, PBMC from subjects who did not
experience a DENV infection during the 5-year study period
had higher antibody titers at baseline and maintained broadly
reactive memory B cell responses over the 5-year period. Our
data demonstrate persistent memory B cell responses over years
and a lasting but variable impact of secondary DENV infection
on DENV-specific T cell responses.
MATERIALS AND METHODS
Study Subjects
Subjects were selected from a 5-year prospective cohort study
in Thailand that has been described elsewhere (24). In brief,
blood samples from schoolchildrenwere collected during January
of every year from 1998 to 2002. PBMC were cryopreserved
in liquid nitrogen until used. In addition, sera were collected
in June, August, and November of each year. Surveillance for
school absences and febrile illnesses was conducted between June
and November each year; acute and convalescent blood samples
were collected from children with fever or history of fever.
Symptomatic DENV infection was identified by febrile illness
with laboratory confirmation of acute DENV infection defined
by virus isolation and/or reverse transcriptase polymerase chain
reaction (RT-PCR) in acute serum samples or seroconversion
between acute and convalescent serum samples by IgM/IgG
ELISA or hemagglutination inhibition (HAI) assay. Subclinical
infection was defined by the absence of symptoms and ≥4-fold
increase in HAI antibody titer from June–August or August–
November. Acute primary or secondary DENV infection were
distinguished by IgM/IgG ratio and HAI titers as previously
described (24, 25). Subjects who consistently had no detectable
antibody or stable (<4-fold change) antibody titer by HAI
assay over the 5-year period were defined as having had no
DENV infection during the study. Written informed consent was
obtained from each subject or his/her parent or guardian. The
study protocol was approved by the Institutional Review Board of
the Thailand Ministry of Public Health, the Human Use Review
and Regulatory Agency of the Office of the U.S Army Surgeon
General and the Institutional Review Board of the University of
Massachusetts School of Medicine.
Detection of Memory B Cell-Derived Total
IgG, DENV-Specific IgG, and
DENV-Specific IgG Subclasses
Approximately 1–2× 106 PBMC were stimulated with 2.5µg/ml
of R848 (Invitrogen, San Diego, CA, USA) and 1,000 U/ml
of IL-2 (Peprotech, Rocky Hill, NJ, USA) in a 48 well plate
for 7 days at 37◦C and 5% CO2. Culture supernatants were
tested for total IgG by Human IgG ELISA Quantitation Set
according to the manufacturer’s instructions (No. E80-104,
Bethyl Laboratories, Inc., Montgomery, TX, USA). Total IgG
levels in the supernatants from stimulated PBMC ranged
from 4.21 to 32.73µg/ml (mean 16.92µg/ml). Samples with a
concentration below the limit of detection (1.56µg/ml) were
excluded. DENV-specific IgG and the four IgG subclasses (IgG1-
4) were detected in the supernatant by ELISA. Briefly, 96 well
plates were coated overnight with 10 ng/well of DENV1-4 virus-
like particles (VLPs) (Native Antigen Company). The plates were
blocked for 90min with 1% BSA. The diluted culture supernatant
was added to the wells for 60min. Plates were washed and goat
anti-human IgG coupled to HRP (A80-104P; Bethyl Laboratories
Inc., Montgomery, TX, USA) was added for total DENV-specific
IgG detection. HRP conjugated secondary antibodies for IgG
subclasses detection include goat anti-human IgG1 FC (9054-05),
IgG1 hinge (9052-05), IgG2 FC (9060-05), IgG3 hinge (9210-05),
and IgG4 FC (9200-05); all were from Southern Biotechnology
Associates, Birmingham, AL, USA. The assay was developed with
TMB substrate (34021; Thermo Scientific, MA, USA), stopped
with 1M HCL, and read at 450 nm.
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Peptide Pools
To evaluate memory T cell responses, we used four peptide pools
spanning the prM and E proteins from DENV1-4, four peptide
pools spanning NS1, NS3, and NS5 proteins (NSA pools) from
DENV1-4, and one peptide pool spanning NS2a/b, NS4a/b, and
C protein from DENV2 (NSB pool). Peptide pools contained
peptides that ranged in length from 12 to 20 amino acids (aa),
in overlap from 10 to 14 aa. The total number of peptides
per pool ranged from 88 to 323 aa (Table S1). Peptides were
obtained from NIH Biodefense & Emerging Infections Research
Resources Repository (BEI Resources, Bethesda, MD, USA) and
Peptide technologies (JPT, Acton, MA, USA). Further details of
the peptides are available at http://www.beiresources.org/.
Ex vivo Dual Color IL-2 and IFN-γ
Enzymatic ELISPOT Assay
The ELISPOT assay was performed according to the
manufacturer’s instructions (CTL, Cleveland, OH, USA).
Cryopreserved PBMC were thawed and plated at a density
of 1–2 × 105 cells/well. Peptide pools were added at a final
concentration of 2 µg/ml/peptide. As a positive control, PBMC
were incubated with anti-CD3 and anti-CD28 antibodies at final
concentrations of 1 and 0.1µg/ml, respectively. As a negative
control, PBMC were incubated with medium. PBMC were
stimulated for 45 h at 37◦C with 5% CO2. As a positive control,
every plate had PBMC from a well-characterized DENV-immune
subject tested with the same conditions. The number of spots
per well was determined using an automated ELISPOT reader
(S5UV analyzer, CTL, Cleveland, OH, USA) with the double
color software. Determinations from duplicate wells were
averaged. Data were analyzed by subtracting the mean number
of spots in the wells with cells and medium-only from the mean
counts of spots in wells with cells and antigen and expressed
as spot-forming cells (SFC) per 106 PBMC. If the response
to anti-CD3/CD28 antibodies was below 500 IFN-γ SFC per
million PBMC, the sample was excluded.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
software V 8.00 (GraphPad Software Inc., La Jolla, CA). The
non-parametric Mann-Whitney U or Wilcoxon signed rank test
was used to compare two groups as appropriate. Statistical
significance was set at P < 0.05.
RESULTS
Characteristics of the Study Population
PBMC from 27 subjects were selected for study based on
available data from 5-years of follow-up (Table S2). Sixteen
subjects were selected for B cell assays: six who had symptomatic
DENV infection, four who had a subclinical infection and six
subjects with no DENV infection. Twenty-five subjects were
selected for T cell assays: 13 who had a symptomatic secondary
DENV infection (six with DENV1, six with DENV2, and one
without a serotype determined), six who had a subclinical
infection, and six with no DENV infection. For the symptomatic
and subclinical infection groups, we selected subjects who
experienced an infection in the first or second year of the study
to allow us to test PBMC collected 1–2 years before and 3–
4 years after secondary DENV infection. HAI antibody titers
to the four DENV serotypes at baseline (start of the study)
were higher in the subclinical and no DENV infection groups
compared to the symptomatic DENV1 and DENV2 groups
(p < 0.05) (Figure S1).
Memory B Cell Responses to DENV
To study the dynamics, magnitude, and durability of the
memory B cell (MBC) responses to DENV, PBMC from 16
subjects were stimulated with IL-2 plus R848. Dengue-specific
IgG antibodies were assessed in supernatants of stimulated
PBMC by ELISA using VLPs from each of the four DENV
serotypes (Figures 1A–C). A total of 74 PBMC samples were
analyzed. DENV-specific MBC responses were low to the
infecting serotype prior to secondary DENV infection in
hospitalized subjects 7, 13, 14, and 15 while they were high to
all four serotypes in two subjects who were not hospitalized
(Figure 1A, Figure S2A). For some subjects, MBC responses
were low to one or more additional DENV serotypes. MBC
responses increased in the first year after infection, with cross-
reactivity to all four serotypes suggesting an expansion of DENV-
cross-reactive B cells (Figure 1A, Figure S2). The increased
MBC response was maintained in PBMC from two of four
hospitalized individuals with symptomatic infection (subjects
13 and 14) for at least 3–4 years after infection (Figure 1A).
In contrast, MBC responses to all four DENV serotypes were
high and persisted over the 5 years in 2 of 4 subjects with
subclinical infection and 5 of 6 subjects studied who did
not experience a DENV infection over the 5-year period of
observation (Figures 1B,C). Serial dilution of supernatants did
not reveal preferential binding to a specific DENV serotype
(Figure 1D, Figure S2). DENV-specific antibodies detected
in MBC culture supernatants were predominantly of the
IgG1 subclass (Figures 1E,F). IgG subclass-specific responses
did not differ between subjects with symptomatic vs. no
DENV infection.
Memory T Cell Responses to DENV
To assess the dynamics, magnitude, and durability of thememory
T cell responses to DENV, 106 PBMC samples from 25 subjects
were stimulated with peptide pools of structural and non-
structural proteins. DENV-specific memory T cells producing
IFN-γ, IL-2, or IFN-γ/IL-2 were determined by dual color
ELISPOT. Because of the limited number of cells available,
PBMC from subjects who experienced a symptomatic DENV1
or DENV2 infection were stimulated with DENV1 or DENV2
prM/E peptides, respectively, in addition to all non-structural
peptide pools. PBMC from subjects with a subclinical or no
DENV infection were stimulated with prM/E peptides from all
four DENV serotypes in addition to the non-structural peptide
pools (Table S1).
Overall, T cell responses to DENV peptide pools
demonstrated a hierarchy of cytokine production of IFN-γ
> IL-2 > IFN-γ/IL-2 in all subjects (Figure S3). DENV-specific
IFN-γ responses were low or absent prior to symptomatic DENV
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FIGURE 1 | Memory B cell responses to DENV. Peripheral blood mononuclear cells from 6 subjects with symptomatic secondary DENV infection (subjects 2 and 5
were not hospitalized, subjects 7, 13, 14, and 15 were hospitalized) (A), 4 subjects with subclinical infection (B), and 6 subjects with no DENV infection (C) were
cultured with R848 plus IL-2 for 7 days and supernatants were tested for DENV-specific IgG Abs. Representative data of supernatant dilution from a subject with
symptomatic and no DENV infection (D). DENV-specific IgG isotypes in supernatants from the year 2000 in 4 subjects with DENV and 4 subjects with no DENV,
respectively (E,F). Bars represent mean with standard error of the mean of the OD values. The asterisk indicates the approximate time when DENV infection occurred.
NI, not included.
infection. Responses increased after infection in most of the
subjects (Figure 2, Figure S4). However, the peak frequency
of DENV-specific IFN-γ-producing memory T cells was not
uniformly detected in the first sample collected after infection.
Overall, the difference in magnitude of DENV-specific IFN-γ
responses before vs. after infection did not reach statistical
significance. DENV-specific T cells were somewhat more stable
over the 5-year period in subjects who did not experience a
DENV infection (Figure 2).
DENV-specific IFN-γ responses in PBMC collected in the first
year of the study (baseline responses) reflect immune responses
potentially predictive of outcome. There were no significant
differences in baseline DENV-specific IFN-γ responses between
subjects who subsequently had a symptomatic infection vs. those
who had a subclinical infection. However, baseline responses
tended to be higher in subjects who did not experience a
DENV infection compared to the other groups (symptomatic or
subclinical DENV infection; Figure S5).
DENV-specific IFN-γ responses in PBMC collected in later
years of the study assess the effects of secondary DENV
infection on memory T cell responses. There was a trend
toward higher IFN-γ responses following symptomatic DENV1
infection compared to the other groups (symptomatic DENV2,
subclinical or no DENV infection), but this did not reach
statistical significance (Figure 2, Figure S6). As expected, PBMC
collected post-infection showed IFN-γ responses to more than
one DENV serotype (Figure 2).
DISCUSSION
We conducted a longitudinal analysis of memory B and T
cell responses to DENV over a 5-year period in primary
schoolchildren living in a dengue-endemic area. Subjects were
chosen to elucidate the impacts of incident DENV infections,
both clinical and subclinical, on DENV-specific immunological
memory, to follow changes in DENV-specific immunological
memory over 3+ years after infection, and to compare
findings in subjects who had symptomatic, subclinical, or no
DENV infections during the study period. Other studies have
measured memory B and T cell responses to DENV, however,
these have largely been cross-sectional studies of individuals
following natural DENV infection or vaccination (19, 26–33).
The longitudinal nature of our study, availability of PBMC
samples both before and after DENV infection, and the inclusion
of groups with different DENV experience led to several
novel observations.
Our assay of memory B cell responses to DENV used ELISA
to evaluate binding to virions by antibodies secreted from
circulating memory B cells after in vitro stimulation. Responses
were detected in PBMC collected prior to an incident DENV
infection. This finding is consistent with the known high baseline
seroprevalence in this population and supports the secondary
nature of most infections in our cohort even when titers of HAI
and neutralizing antibody were undetectable (15, 34, 35). These
samples also showed lower responses to one or more serotype(s),
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FIGURE 2 | IFN-γ ELISPOT responses in individual subjects. DENV peptide-specific interferon γ (IFN-γ) spot-forming cells (SFC) were determined by dual color
ELISPOT in PBMC collected at the indicated time points. PBMC were collected at the beginning of each year. Subjects who experienced a (A) DENV1 infection (B)
DENV2 infection (C) subclinical dengue infection and (D) no dengue infection over the 5-year period. Bars represent mean with standard error of the mean for
duplicate wells. The asterisk indicates the approximate time when DENV infection occurred. NT, not tested; NI, not included.
which in each case included the serotype that caused the next
infection. This finding suggests that assays of memory B cells
might help to assess susceptibility to infection among DENV-
experienced individuals, which has been difficult to define based
on serum assays (14, 36). The high responses to all four serotypes
in study subjects who did not experience a DENV infection may
therefore reflect protective immunity in those subjects (37).
Following an incident DENV infection, memory B cell
responses increased in magnitude and breadth, consistent with
a model wherein serotype-cross-reactive memory B cells are
preferentially expanded by sequential DENV infections (32,
33, 38). However, while memory B cell responses increased
in the earliest blood sample collected after infection, there
was substantial heterogeneity in the durability of this increase
between study subjects and, for each subject, across viral
serotypes. Human memory B cells have been detected decades
after infection or vaccination, but are less durable for some
vaccines and pathogens (39–44). Our data imply an important
role of subject-specific and cell-intrinsic factors in the durability
of DENV-specific memory B cells (44). Further studies are
needed to define these factors and their relationship to
susceptibility or resistance to subsequent DENV infection
or disease.
We measured memory T cell responses to DENV using dual
IFN-γ/IL-2 ELISPOT assays and stimulation with overlapping
peptide pools. In contrast to memory B cell responses, we did
not detect memory T cell responses in all subjects. Whereas,
some studies of adult volunteers after natural DENV infection
or administration of live virus vaccine candidates have reported
DENV-specificmemory T cell responses in nearly all subjects (26,
45, 46), our results are in line with other cross-sectional studies
of dengue-endemic populations (15, 16, 19, 27, 29, 47–50). Other
factors that may contribute to lower memory T cell responses in
our study include the young age of our subjects, the number of
prior exposures to DENV, and other endemic infections (51, 52).
Memory T cell responses were generally lower in those subjects
who experienced a symptomatic DENV infection, as we observed
for memory B cells. There have been very few prospective studies
of DENV-specific memory T cell responses in PBMC collected
prior to secondary DENV infection (15, 49, 53). An inverse
relationship was previously found in our cohort between DENV-
specific T cell responses measured by intracellular staining for
IFN-γ or IL-2 and symptomatic DENV infection (15). Others
reported an inverse correlation between DENV-specific IFN-γ
ELISPOT responses and HLA class I-related susceptibility to
dengue (16).
Memory T cell responses to DENV were higher in the PBMC
collected after an incident DENV infection, but these responses
were quite variable over a 3-year period, and responses were not
consistently highest in the samples collected closest in time to
the infection. Previous studies have either been cross-sectional in
nature (26, 27, 29, 30) or covered a short time period (46, 47, 54),
and therefore are not directly comparable to our findings. It
is possible that measurement of other T cell functions would
have reflected different trends in cell frequency (55–57). Given
ongoing DENV transmission in the study area throughout the
period of observation, it is also possible that some subjects
experienced additional exposures to DENV that modulated T
cell frequency but were not detected as significant increases in
antibody titer.
Our findings must be interpreted in the context of several
limitations of our study design. The quantity of PBMC available
from the small blood volumes collected from young children
was a major consideration for assay design. As a result, we
could not test all antigen specificities or effector functions of
memory B and T lymphocytes. Antibody responses to NS1 (58),
T cell responses to other structural and non-structural antigens
(59, 60), and multiparameter single-cell analyses (46, 61) would
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be of interest and might modify some of our conclusions. We
used pools containing a large number of overlapping peptides in
T cell ELISPOT assays, which has been reported to be suboptimal
for detection of responses (19, 46, 62–64). We studied memory
T and B cell responses in PBMC; lymphocyte repertoires in
blood and tissue have been shown to differ in some infections,
such as influenza (65). As DENV causes systemic infection,
the most relevant tissues have not been defined, and most
other studies of the immune repertoire have utilized PBMC.
The narrow criteria we used for selection of cohort subjects
limited the number available for these studies and reduced
the statistical power for comparisons between groups. Our
cohort study design along with these criteria also restricted
the age range, host genetics, and geographic distribution of
study subjects, which is likely to have limited the diversity of
prior DENV infection history (66). Comparable studies in other
populations will be needed to determine the generalizability of
our findings.
Overall, this longitudinal analysis of memory B and T cell
responses to DENV and the impacts of intervening symptomatic
and subclinical DENV infections supports the paradigm of
selective expansion of DENV-specific immunological memory
by sequential exposures, but reveals additional heterogeneity
between and within individual subjects than could be ascertained
from cross-sectional studies. This heterogeneity should be
considered in the interpretation of data from cohort studies of
natural DENV infection and clinical trials of dengue vaccines.
We suggest that further studies are warranted to evaluate the
associations with susceptibility vs. resistance to DENV infection
and disease.
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